All In Biotech

Drug Trial Radar · NCT07043400

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 351 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

351

Planned (sponsor's estimate)

Start

Aug 27, 2025

Primary completion

Oct 30, 2027

Study completion Apr 22, 2028

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jun 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.

Conditions

  • Metastatic Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • Subcutaneous TislelizumabDrug

    Administered by subcutaneous injection

  • Intravenous TislelizumabDrug

    Administered by intravenous infusion

  • CisplatinDrug

    Administered by intravenous infusion

  • LeucovorinDrug

    Administered by intravenous infusion

  • 5-fluorouracil (5-FU)Drug

    Administered by intravenous infusion

  • OxaliplatinDrug

    Administered by intravenous infusion

  • CapecitabineDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Model-Predicted Steady State Trough Concentration (Ctrough) of TislelizumabTime frame: 85 Days
  2. Model-Predicted Area under the Concentration-time Curve from Time Zero to 21 Days (AUC0-21d) after the First Dose of TislelizumabTime frame: 21 Days

Locations

95 sites in 16 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers Chandler Ii

    Chandler, Arizona · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • UC Health Cancer Care and Hematology Clinic Memorial Hospital Central

    Colorado Springs, Colorado · Recruiting

  • Bioresearch Partners Holding Hialeah Hospital

    Hialeah, Florida · Recruiting

  • Orlando Health Cancer Institute Downtown Orlando

    Orlando, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Recruiting

  • University of Kansas Medical Center Research Institute

    Kansas City, Kansas · Recruiting

  • New England Cancer Specialists

    Westbrook, Maine · Recruiting

  • St Louis Cancer Care, Llp

    Bridgeton, Missouri · Recruiting

  • Nebraska Hematology Oncology

    Lincoln, Nebraska · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

  • Hunterdon Hematology Oncology

    Flemington, New Jersey · Recruiting

  • Summit Medical Group

    Florham Park, New Jersey · Recruiting

  • Oregon Oncology Specialists

    Salem, Oregon · Recruiting

  • Vanderbilt University

    Nashville, Tennessee · Recruiting

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Baylor Scott and White Medical Center Temple

    Temple, Texas · Recruiting

  • Northwest Medical Specialties

    Tacoma, Washington · Recruiting

  • Hospital Aleman

    Caba, Argentina · Recruiting

  • Instituto Alexander Fleming (Iaf)

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Fundacion Cori Para La Investigacion Y Prevencion Del Cancer

    La Rioja, Argentina · Recruiting

  • Krankenhaus Der Barmherzigen Schwestern Linz

    Linz, Austria · Recruiting

  • Medical Univeristy Vienna

    Vienna, Austria · Recruiting

  • Hospital de Amor Barretos

    Barretos, Brazil · Recruiting

  • CECAP

    Blumenau, Brazil · Recruiting

  • Hospital Brasilia

    Brasília, Brazil · Recruiting

  • Hospital Universiario Onofre Lopes

    Natal, Brazil · Recruiting

  • Hospital Sao Lucas Da Pucrs

    Porto Alegre, Brazil · Recruiting

  • IMIP

    Recife, Brazil · Recruiting

  • Inca Instituto Nacional de Cancer

    Rio de Janeiro, Brazil · Recruiting

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

    São José do Rio Preto, Brazil · Recruiting

  • Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira

    São Paulo, Brazil · Recruiting

  • Instituto Dor de Pesquisa E Ensino Sao Paulo

    São Paulo, Brazil · Recruiting

  • Hospital Santa Rita de Cassia Afecc

    Vitória, Brazil · Recruiting

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Anyang Tumor Hospital

    Anyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.